Skip to main content

Table 2 Multivariate analysis for predictors of MDD recurrence

From: Patterns of hypnotic prescribing for residual insomnia and recurrence of major depressive disorder: a retrospective cohort study using a Japanese health insurance claims database

Variable Reference Category MDD recurrence at 360 days, OR (95% CI)
Prescription pattern Benzodiazepine Non-benzodiazepine 0.84 (0.67–1.07)
Melatonin receptor agonist 0.87 (0.47–1.60)
Orexin receptor antagonist 0.87 (0.50–1.50)
Combination therapy (2 drugs) 1.23 (0.97–1.56)
Combination therapy (3 drugs) 0.91 (0.60–1.37)
Combination therapy (≥4 drugs) 0.97 (0.53–1.75)
Gendera Male Female 0.67 (0.50–0.88)
Agea < 40 years ≥40 years 0.95 (0.78–1.14)
Insured or dependent Insured Spouse 1.44 (1.03–2.02)
Other family member 1.46 (0.99–2.16)
Prior neurological medication, psychotropic drug Absent Present 1.22 (0.86–1.73)
Prior anxiolytic medication Absent Present 0.98 (0.77–1.24)
Concomitant antipsychotic medication Absent Present 1.11 (0.88–1.39)
Sedative antidepressant Absent Present 1.50 (1.24–1.82)
Antidepressant dosage at end of treatment <Recommended maximum dose ≥Recommended maximum dose 1.11 (0.77–1.60)
Antidepressant dosage (mg/day)b < 75 mg/day ≥75 and < 150 mg/day 1.06 (0.86–1.29)
≥150 mg/day 1.14 (0.81–1.61)
  1. aMandatory variables; bConverted to values that are equivalent to imipramine using a dose-equivalence scale for antidepressants [20].
  2. CI Confidence interval, MDD Major depressive disorder, OR Odds ratio